These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26577941)

  • 1. The role of patient-based treatment planning in peptide receptor radionuclide therapy.
    Hardiansyah D; Maass C; Attarwala AA; Müller B; Kletting P; Mottaghy FM; Glatting G
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):871-880. PubMed ID: 26577941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model.
    Hardiansyah D; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
    Phys Med; 2017 Oct; 42():298-304. PubMed ID: 28739143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment planning in PRRT based on simulated PET data and a PBPK model. Determination of accuracy using a PET noise model.
    Hardiansyah D; Guo W; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
    Nuklearmedizin; 2017 Feb; 56(1):23-30. PubMed ID: 27885372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy.
    Hardiansyah D; Begum NJ; Kletting P; Mottaghy FM; Glatting G
    Cancer Biother Radiopharm; 2016 Aug; 31(6):217-24. PubMed ID: 27403777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy.
    Kletting P; Kull T; Maaß C; Malik N; Luster M; Beer AJ; Glatting G
    J Nucl Med; 2016 Apr; 57(4):503-8. PubMed ID: 26678617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.
    Hardiansyah D; Guo W; Kletting P; Mottaghy FM; Glatting G
    Med Phys; 2016 Sep; 43(9):5145. PubMed ID: 27587044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.
    Kaewput C; Vinjamuri S
    Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model.
    Hardiansyah D; Riana A; Beer AJ; Glatting G
    Z Med Phys; 2023 Feb; 33(1):70-81. PubMed ID: 35961809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
    Gupta SK; Singla S; Bal C
    Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule.
    Maaß C; Sachs JP; Hardiansyah D; Mottaghy FM; Kletting P; Glatting G
    EJNMMI Res; 2016 Dec; 6(1):30. PubMed ID: 27015662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based pharmacokinetic modeling of (18)F-SiFAlin-Asp3-PEG1-TATE in AR42J tumor bearing mice.
    Maaß C; Rivas JR; Attarwala AA; Hardiansyah D; Niedermoser S; Litau S; Wängler C; Wängler B; Glatting G
    Nucl Med Biol; 2016 Apr; 43(4):243-6. PubMed ID: 27067044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
    Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in
    Jiménez-Franco LD; Glatting G; Prasad V; Weber WA; Beer AJ; Kletting P
    J Nucl Med; 2021 Jan; 62(1):92-98. PubMed ID: 32646878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue.
    Giesel FL; Stefanova M; Schwartz LH; Afshar-Oromieh A; Eisenhut M; Haberkorn U; Kratochwil C
    Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):171-6. PubMed ID: 23370092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized kidney dosimetry in
    Hou X; Zhao W; Beauregard JM; Celler A
    Phys Med Biol; 2019 Aug; 64(17):175004. PubMed ID: 31456584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.